Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 19, 2023

Addition of Docetaxel to Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials
Lancet Oncol 2023 Jul 01;24(7)783-797, CL Vale, DJ Fisher, PJ Godolphin, LH Rydzewska, JM Boher, S Burdett, YH Chen, NW Clarke, K Fizazi, G Gravis, ND James, G Liu, D Matheson, L Murphy, RE Oldroyd, MKB Parmar, E Rogozinska, P Sfumato, CJ Sweeney, MR Sydes, B Tombal, IR White, JF Tierney

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading